- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- New York's online database of drug prescriptions curtailing 'doctor shopping'
- Actavis seeks approval for generic opioid-dependence drug
- EXPERT BLOG: Provider status for pharmacists — one way or another
RICHMOND, Va. The Food and Drug Administration has approved Reckitt Benckiser’s treatment for opioid addiction, Reckitt Benckiser said.
The drug maker announced the approval of Suboxone (buprenorphine and naloxone), a drug delivered through a fast-dissolving film placed under the tongue. The film is based on a technology known as PharmFilm, made by MonoSol Rx.
“The development of Suboxone sublingual film through our exclusive agreement with MonoSol Rx reinforces our commitment to our opioid dependence therapy franchise and to its development,” Reckitt Benckiser president Shaun Thaxter said.